Brief: Arctic Bioscience H1 Adjusted EBITDA Loss Widens To NOK 20.9 Mln

Arctic Bioscience AS

29/08/2024 07:12

Aug 29 (Reuters) - Arctic Bioscience AS  ABSA.OL :
    * STUDY DE-RISKED BY ALL NEEDED PATIENTS PASSED 6 MONTHS,
READ-OUT
EXPECTED IN 4-6 WEEKS
    * 6-MONTHS PRIMARY END-POINT READ-OUT IS EXPECTED ULTIMO
SEPTEMBER/EARLY OCTOBER
    * REVENUE PROSPECTS FOR H2 2024 ARE POSITIVE
    * NUTRA REVENUES IN H1 2024 TOTALLING NOK 16,7 MILLION (NOK
19,1
MILLION)
    * H1 ADJUSTED EBITDA: NOK -20,9 MILLION (NOK -18,3 MILLION)

Source text for Eikon:  ID:nWkr9jhCF9 
Further company coverage:  ABSA.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))